Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease

• US 7,812,124 B2
• Filed: 11/30/2006
• Issued: 10/12/2010
• Est. Priority Date: 11/16/2000
• Status: Expired due to Fees

• Current Assignee: Kaia Palm
• Original Assignee: Kaia Palm
• Inventors: Palm, Kaia
• Primary Examiner(s): Helms; Larry R.
• Assistant Examiner(s): DAVIS, MINH TAM B
• Application Number:
  US11/606,786
• Publication Number:
  US 20070161023A1
• Time in Patent Office: 1,412 Days
• Field of Search: 530/350, 435/7.1
• US Class Current: 530/350
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: G01N 33/574 for cancer

Abstract

A method of diagnosing cancer comprising the identification of neoplastic molecular markers is disclosed. Tumor-related or neoplastic molecular markers are identified from samples taken from a subject and the molecular profile of those markers is determined. Based upon the neoplastic molecular marker profile of the subject, the tumor sub-type is ascertained and an appropriate treatment protocols initiated.

Claims

1. An array for identifying a neoplastic source sample, comprising a plurality of neoplastic molecular markers arranged in an assayable format, said molecular markers being differentially expressed in a sample obtained from a subject afflicted with small cell lung cancer as compared to a comparable sample obtained from a subject not afflicted with small cell lung cancer;

wherein said neoplastic molecular markers comprise protein markers of NeuroD2, ATH5, Sox1, Sox2, and LMO4; and

wherein said protein markers are used to detect the presence of small cell lung cancer.

2. The array of claim 1, wherein said protein markers comprise peptides of NeuroD2, ATH5, Sox1, Sox2, and LMO4.

3. The array of claim 1, wherein said neoplastic molecular markers further comprise at least one protein marker selected from the group consisting of HES2, Isl1, Lhx2, NeuroD1, NGN2, NSCL2, Sharp1, Groucho1, Sox10, Sox11, Sall1, GBX2, and Brn5, or combinations thereof.